Table 4 Multivariate Cox regression analyses for MACE in the study population.

From: Triglyceride-glucose body mass index predicts prognosis in patients with ST-elevation myocardial infarction

 

HR (95% CI)

 

Model

Q1

Q2

Q3

p for trend

MACE

 Numbers of events/total

46/883

68/882

79/883

 

 Model 1

1 [Reference]

1.48(1.01, 2.16) *

1.75(1.20, 2.56) *

0.004

 Model 2

1 [Reference]

1.42(0.97, 2.09)

1.56(1.05, 2.31) *

0.026

 Model 3

1 [Reference]

1.37(0.92, 2.03)

1.53(1.02, 2.29) *

0.038

All cause death

 Numbers of events/total

19/883

22/882

26/883

 

 Model 1

1 [Reference]

1.34(0.72, 2.52)

1.93(1.03, 3.62) *

0.039

 Model 2

1 [Reference]

1.19(0.62, 2.26)

1.48(0.76, 2.87)

0.249

 Model 3

1 [Reference]

1.02(0.52, 2.01)

1.49(0.75, 2.95)

0.258

Revascularization

 

 Numbers of events/total

23/883

30/882

39/883

 

 Model 1

1 [Reference]

1.24(0.72, 2.14)

1.57(0.92, 2.67)

0.097

 Model 2

1 [Reference]

1.23(0.70, 2.14)

1.54(0.89, 2.69)

0.126

 Model 3

1 [Reference]

1.24(0.70, 2.18)

1.59(0.90, 2.82)

0.109

Non-fatal MI

 Numbers of events/total

12/883

17/882

23/883

 

 Model 1

1 [Reference]

1.61(0.75, 3.45)

2.44(1.16, 5.15) *

0.019

 Model 2

1 [Reference]

1.55(0.72, 3.33)

2.34(1.08, 5.08) *

0.031

 Model 3

1 [Reference]

1.21(0.54, 2.71)

2.25(1.00, 5.08)

0.050

Non-fatal stroke

 Numbers of events/total

2/883

4/882

11/883

 

 Model 1

1 [Reference]

2.59(0.45, 15.0)

6.82(1.36, 34.3) *

0.020

 Model 2

1 [Reference]

2.62(0.42, 16.2)

5.73(1.00, 32.8)

0.050

 Model 3

1 [Reference]

2.71(0.38,19.0)

7.20(1.11, 46.5) *

0.038

  1. Model 1: adjusted for age and gender; Model 2: further adjusted (from Model 1) for smoker, drinker, Hypertension, Diabetes, Previous MI, Previous PCI, Previous stroke, Previous arrhythmia, FH-CAD, Thrombolysis, Multi-vessel disease, Stenting, Timely PCI, LVEF, LVEDD; Model 3: further adjusted (from Model 2) for Killip class ≥ 2, anterior MI on ECG , TIMI grade 0–1 fow before PCI , Time from symptom onset to hospital arrival, TC, LDL-C, HDL-C, CK, CKMB, TnT, D-dimer, BUN, Ccr, use of ACEI/ARB, Beta-blockers, and CCB drugs. MACE major adverse cardiovascular events, HR hazard ratio, CI confidence interval, PCI percutaneous coronary intervention, MI myocardial infarction, FH-CAD family history of coronary artery disease, HR heart rate, BUN Blood urea nitrogen, Ccr creatinine clearance rate, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TnT Troponin T, CK creatine kinase, CK-MB creatine kinase-MB, LVEF left ventricle ejection fraction, LVEDD left ventricular end-diastolic dimension, ACEI angiotensin II coenzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker, TIMI Thrombolysis In Myocardial Infarction.
  2. *p < 0.05.
Back to article page